Tirzepatide certificates of analysis (COA)
20 released lots of Tirzepatide (CAS 2023788-19-2). Each lot is tested in the manufacturer's laboratory for purity by reverse-phase HPLC and for identity by LC-MS before release, and the lot number printed on every unit matches its certificate. Open a certificate for the full results, or confirm it with its number and key on Verify a certificate.
| Lot | Size | Certificate | Purity (RP-HPLC) | Identity (LC-MS) | Tested |
|---|---|---|---|---|---|
| PL-2610-224 | 100 mg | PL-26-00337 | 99.15% | Conforms (4,813.17 Da) (expected 4813.45 Da, found 4813.17 Da) | October 8, 2026 |
| PL-2610-223 | 80 mg | PL-26-00336 | 99.34% | Conforms (4,813.72 Da) (expected 4813.45 Da, found 4813.72 Da) | October 8, 2026 |
| PL-2610-222 | 60 mg | PL-26-00335 | 99.25% | Conforms (4,813.47 Da) (expected 4813.45 Da, found 4813.47 Da) | October 8, 2026 |
| PL-2610-221 | 50 mg | PL-26-00334 | 99.28% | Conforms (4,813.74 Da) (expected 4813.45 Da, found 4813.74 Da) | October 8, 2026 |
| PL-2610-220 | 40 mg | PL-26-00333 | 99.37% | Conforms (4,813.23 Da) (expected 4813.45 Da, found 4813.23 Da) | October 8, 2026 |
| PL-2610-219 | 30 mg | PL-26-00332 | 99.22% | Conforms (4,813.49 Da) (expected 4813.45 Da, found 4813.49 Da) | October 8, 2026 |
| PL-2610-218 | 20 mg | PL-26-00331 | 99.33% | Conforms (4,813.67 Da) (expected 4813.45 Da, found 4813.67 Da) | October 8, 2026 |
| PL-2610-217 | 15 mg | PL-26-00330 | 99.25% | Conforms (4,813.49 Da) (expected 4813.45 Da, found 4813.49 Da) | October 8, 2026 |
| PL-2610-216 | 10 mg | PL-26-00329 | 99.30% | Conforms (4,813.44 Da) (expected 4813.45 Da, found 4813.44 Da) | October 8, 2026 |
| PL-2610-215 | 5 mg | PL-26-00328 | 99.39% | Conforms (4,813.42 Da) (expected 4813.45 Da, found 4813.42 Da) | October 8, 2026 |
| PL-2609-117 | PL-26-00117 | 99.29% | Conforms (4813.6 Da) (expected 4813.5 Da, found 4813.6 Da) | September 19, 2026 | |
| PL-2609-116 | PL-26-00116 | 99.21% | Conforms (4813.3 Da) (expected 4813.5 Da, found 4813.3 Da) | September 19, 2026 | |
| PL-2609-115 | PL-26-00115 | 99.27% | Conforms (4813.7 Da) (expected 4813.5 Da, found 4813.7 Da) | September 19, 2026 | |
| PL-2609-114 | PL-26-00114 | 99.24% | Conforms (4813.2 Da) (expected 4813.5 Da, found 4813.2 Da) | September 19, 2026 | |
| PL-2609-113 | PL-26-00113 | 99.32% | Conforms (4813.8 Da) (expected 4813.5 Da, found 4813.8 Da) | September 19, 2026 | |
| PL-2609-112 | PL-26-00112 | 99.26% | Conforms (4813.4 Da) (expected 4813.5 Da, found 4813.4 Da) | September 19, 2026 | |
| PL-2609-111 | PL-26-00111 | 99.23% | Conforms (4813.6 Da) (expected 4813.5 Da, found 4813.6 Da) | September 19, 2026 | |
| PL-2609-110 | PL-26-00110 | 99.30% | Conforms (4813.3 Da) (expected 4813.5 Da, found 4813.3 Da) | September 19, 2026 | |
| PL-2609-109 | PL-26-00109 | 99.25% | Conforms (4813.7 Da) (expected 4813.5 Da, found 4813.7 Da) | September 19, 2026 | |
| PL-2609-108 | PL-26-00108 | 99.28% | Conforms (4813.4 Da) (expected 4813.5 Da, found 4813.4 Da) | September 19, 2026 |
Reading these certificates
HPLC purity is the share of UV-detectable material that elutes as the target compound; it is not the same as net peptide content, which also accounts for water and counter-ions. Identity means the measured mass matched the mass calculated for the compound. See how to read a certificate of analysis and HPLC and mass spectrometry explained.
Tirzepatide · All certificates
All products currently listed on this site are for research purposes only. Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption. Products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure or prevent any disease.